CAS RN: 112522-64-2 | Product Number: A2501
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
|Purity / Analysis Method||>98.0%(HPLC)|
|Molecular Formula / Molecular Weight||C__1__5H__1__5N__3O__2 = 269.30|
|Physical State (20 deg.C)||Solid|
|Condition to Avoid||Heat Sensitive|
|PubChem Substance ID||160871335|
|Appearance||Light orange to Yellow to Green powder to crystal|
|Purity(HPLC)||min. 98.0 area%|
|Elemental analysis(Nitrogen)||15.0 to 16.0 %|
|Melting Point||242 °C(dec.)|
Chemical phylogenetics of histone deacetylases
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
M. Bantscheff, C. Hopf, M. M. Savitski, A. Dittmann, P. Grandi, A.-M. Michon, J. Schlegl, Y. Abraham, I. Becher, G. Bergamini, M. Boesche, M. Delling, B. Dümpelfeld, D. Eberhard, C. Huthmacher, T. Mathieson, D. Poeckel, V. Reader, K. Strunk, G. Sweetman, U. Kruse, G. Neubauer, N. G. Ramsden, G. Drewes, Nat. Biotechnol. 2011, 29, 255.
Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head
Preclinical antitumor activity of CI-994
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
C of A & Other Certificates
The requested analytical chart is not available. Sorry for the inconvenience.